Jul 16, 2024 / 12:00PM GMT
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-President - Chief Executive Officer
Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the second-quarter 2024 conference call for investors and analysts. We posted this presentation to sobi.com earlier today.
We would like to remind you, please go to slide number 2 of the usual provisions on statements about expectations and projections of future events. And unless stated otherwise, we will be making comments that mostly relate to the second quarter at constant exchange rate in million Swedish krona.
Please turn to slide number 3. Today, we plan to cover the key aspects of our Q2 report. I'm joined by Henrik Stenqvist, our CFO; Lydia Abad-Franch, our Head of R&D and Chief Medical Officer. During the Q&A session, we will be joined by Armin Reininger, our Senior Scientific Adviser as well. We plan to review the presentation first and then have a Q&A under around 3:00 PM Swedish Time. (Operator Instructions)
With this said, let's go right
Q2 2024 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 16, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers